苏州艾缇克药物化学有限公司

Suzhou ITIC Medchem Co.,Ltd.

NEWS

News & Events

News Details

ITIC Medchem

2021.12.14 The Yangtze River Delta, which accounts for nearly 30% of the national biopharmaceutical output value, why should an alliance be established?

Time: 2022-03-28

For the development of China's biopharmaceutical industry, it has become a top priority to improve the ability of independent innovation, focus on solving major technical problems that hinder the development of the industry, and accelerate the breakthrough of individual enterprises and even the entire industry.

Recently, six units including Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Shangchuang Institute, Hengrui Medicine, Dean Diagnostic Technology Group Co., Ltd., Jiangsu Tianhui Hongyou Investment Management Co., Ltd., and Xinda Biopharmaceutical (Suzhou) Co., Ltd. The founding unit, together with more than 10 other leading units related to pharmaceutical innovation in the Yangtze River Delta, as a co-initiating unit, initiated the establishment of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance in Shanghai.

At present, the output value of biopharmaceuticals in the Yangtze River Delta is close to 30% of the national total, with nearly 30% of the top 100 national pharmaceutical companies and top 100 pharmaceutical R&D companies, contributing nearly 70% of the total number of domestic Class 1 new drugs approved between 2018 and 2020. One of the most competitive and advantageous industries in the Triangle region. The Yangtze River Delta has the conditions and is necessary to strive to become a reform test field, an innovation source and a development demonstration area for the leap-forward development of China's pharmaceutical industry.

Benchmark the top, hold the "bull's nose" to enhance the competitiveness of regional industrial clusters

If we benchmark the four key characteristics of the competitiveness of the international biomedical industry cluster—leading enterprises, innovation strength, collaborative layout and industrial ecology, etc., there is still a certain gap between the Yangtze River Delta and the world's top level.

In this regard, Lu Xiongwen, the main sponsor of the alliance, dean of the School of Business and Innovation, and dean of the School of Management of Fudan University, issued an appeal: Biopharmaceutical companies should cherish and seize the rare opportunity of this round of scientific and technological revolution, face the difficulties and take the initiative. Holding the "bull nose" of the world's cutting-edge medical technology, breaking through the "stuck neck" problem, and contributing to promoting the biomedical industry to become an important part of the national development strategy and the vanguard of China's high-end manufacturing going global. As the tenth innovation platform in the hospital, the Pharmaceutical Innovation Industry Alliance hopes to further promote the integrated development of production, learning and research in the Yangtze River Delta, and promote collaborative innovation and greater progress in the Yangtze River Delta, especially the biomedical industry.

Li Jia, the founding unit of the alliance and director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, said that a series of higher-level issues such as how to leapfrog the development of the Chinese pharmaceutical industry, participate in the international competition of the pharmaceutical industry for the country, and actively explore the new development pattern of medicine are the problems of the alliance colleagues. The shared feeling has also formed a consensus on the orientation and goals of the alliance, which will also be a solid foundation for the alliance to carry out research on related topics and achieve other strategic goals in the future.

Promoting policy innovation, technological innovation and talent development with their respective strengths

" The establishment of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance is not only a major event in the pharmaceutical industry in the Yangtze River Delta region, but also a major event in the national pharmaceutical industry. The alliance is formed by outstanding companies and R&D institutions in the Yangtze River Delta region, with production, learning, research, medicine, and business. Other outstanding entrepreneurs and well-known experts in various fields will participate together to jointly promote the development of the alliance, the Yangtze River Delta and the development of the national pharmaceutical industry." According to Jiang Hualiang, chairman of the alliance and academician of the Chinese Academy of Sciences, during the preparation of the alliance, through a questionnaire Collected more than 10 problems that the sponsors thought about and expected to solve. There are both common problems and individual problems. Each institution has its own division of labor, different development stages, and different challenges in the pharmaceutical innovation ecosystem. The different demands of the problem are the same as our joint efforts to promote the development of the pharmaceutical innovation and development of the Yangtze River Delta and even the whole of China with a global perspective, and the responsibilities and missions that all units need to take on.

The Pharmaceutical Innovation and Development Alliance takes "serving the needs of enterprises, supporting government decision-making, pooling innovative resources, promoting industrial development, and improving industrial ecology" as its purpose, with the promotion of policy innovation, technological innovation and personnel training in the pharmaceutical industry as its main focus, and strives to promote the development of the pharmaceutical industry. In the Yangtze River Delta, set up a pilot demonstration base for pharmaceutical innovation and development or a demonstration area for pharmaceutical innovation and reform, promote the formulation of an integrated development plan for the pharmaceutical industry in the Yangtze River Delta region, and promote the establishment of a think tank and the government to communicate and exchange suggestions. , relieve pain points, promote innovation, and optimize ecology.

At present, there are 20 Chinese medicine enterprises in the 38 alliance members, 10 investment institutions, colleges and universities, and 7 hospitals. The ecological construction covers production, learning, research, medicine, use, Business, construction and other aspects.

"As a medical institution, what role and responsibilities do we need to play in medical innovation, we have a lot of thinking in this." Sun Xiaodong, vice president of Shanghai First People's Hospital, said frankly, such as how to strengthen clinical research capabilities, how to improve Clinical trial capabilities, how to encourage medical staff to take patients as the center to participate in technological innovation and achievement transformation, etc. There are also some practices and explorations that have been working hard, such as the "three emphasis" requirements put forward by the Municipal Party Committee and Municipal Government for the development of Shanghai clinical research institutions. ——Focus on giving full play to the unique advantages, focusing on forming a scientific system, focusing on expanding the cooperation network, and striving to form a batch of iconic original achievements, making Shanghai an internationally leading source of new drugs, new equipment and new devices.

Chen Haibin, vice chairman of the Business Innovation Institute, director of the Great Health Institute, and chairman of Dean Diagnostics, said that the birth of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance is the result of a high degree of consensus, active participation and sharing by all initiators, and it is also the result of all members of the alliance. Consciously monitor the mission and responsibility, and jointly promote the further optimization and improvement of the driving force of the pharmaceutical innovation ecology in the Yangtze River Delta and even in China. This year, Dean Diagnostics and the National Center for Infectious Diseases jointly launched the Yangtze River Delta Infection Precision Diagnosis and Treatment Alliance, and cooperated with the Chinese Medical Association, the School of State Affairs of Fudan University, the Shanghai Academy of Social Sciences and other institutions to carry out related research, and released the "Yangtze River Delta City Public Health Emergency Collaboration" Governance Innovation Research" report, and prepared the Yangtze River Delta Precision Diagnosis and Treatment Alliance.

Lu Tao, vice president of China Pharmaceutical University, said that participating in the establishment of the alliance is not only to look forward to the application and transformation of the resources we have through the alliance, but also to expect more support for our basic research and source innovation. To this end, based on the characteristics of pharmacy, China Pharmaceutical University will give full play to its scientific research and educational advantages in basic research, policy research and personnel training, and firmly grasp the "policy innovation, technological innovation, talent development" determined by the alliance's work plan. These three starting points focus on fully supporting the work of the alliance through participation in the work of the alliance and its related special committees.

Source: Sina.com

QQ: 800101807

Mobile: +86-18015559028

Tel: +86-512-68323967

E-mail: sales@iticmedchem.com

Address: West side of the third floor, Area A, Pilot Base, Hefeng Industrial Park, No. 2 Taishan Road, High-tech Zone, Suzhou City

Copyright(C)2022, Suzhou ITIC Medchem Co., Ltd. All Rights Reserved. Supported by ChinaChemNet ChemNet Toocle Copyright Notice 备案序号:苏ICP备17018514号